Literature DB >> 10770789

Vancomycin and oxacillin synergy for methicillin-resistant staphylococci.

B E Domaracki1, A M Evans, R A Venezia.   

Abstract

An increase in oxacillin activity was observed against methicillin-resistant coagulase-negative staphylococci (MRCNS) and methicillin-resistant Staphylococcus aureus (MRSA) in the presence of a sub-MIC of vancomycin. Vancomycin and oxacillin were synergistic against 14 of 21 strains of MRCNS and MRSA. A pattern of enhanced killing was also supported by time-kill studies. These results suggest that combinations of sub-MICs of vancomycin and oxacillin may have therapeutic benefits against methicillin-resistant staphylococci.

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 10770789      PMCID： PMC89882          DOI： 10.1128/AAC.44.5.1394-1396.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection.

Authors:  K Sieradzki; R B Roberts; S W Haber; A Tomasz
Journal:  N Engl J Med       Date:  1999-02-18       Impact factor: 91.245

2.  Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-08-22       Impact factor: 17.586

3.  Update: Staphylococcus aureus with reduced susceptibility to vancomycin--United States, 1997.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1997-09-05       Impact factor: 17.586

4.  In vitro selection of resistance to vancomycin in bloodstream isolates of Staphylococcus haemolyticus and Staphylococcus epidermidis.

Authors:  L Herwaldt; L Boyken; M Pfaller
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1991-12       Impact factor: 3.267

5.  Decreased susceptibilities to teicoplanin and vancomycin among coagulase-negative methicillin-resistant clinical isolates of staphylococci.

Authors:  K Sieradzki; P Villari; A Tomasz
Journal:  Antimicrob Agents Chemother       Date:  1998-01       Impact factor: 5.191

6.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

7.  Emergence of vancomycin resistance in coagulase-negative staphylococci.

Authors:  R S Schwalbe; J T Stapleton; P H Gilligan
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

8.  Activities of levofloxacin, ofloxacin, and ciprofloxacin, alone and in combination with amikacin, against acinetobacters as determined by checkerboard and time-kill studies.

Authors:  S Bajaksouzian; M A Visalli; M R Jacobs; P C Appelbaum
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

9.  The in-vitro antibacterial activity of a combination of cefpirome or cefoperazone with vancomycin against enterococci and Staphylococcus aureus.

Authors:  G Seibert; D Isert; N Klesel; M Limbert; A Markus; E Schrinner
Journal:  J Antimicrob Chemother       Date:  1992-04       Impact factor: 5.790

10.  Selection for vancomycin resistance in clinical isolates of Staphylococcus haemolyticus.

Authors:  R S Schwalbe; W J Ritz; P R Verma; E A Barranco; P H Gilligan
Journal:  J Infect Dis       Date:  1990-01       Impact factor: 5.226
View more
  12 in total

1.  In vitro activities of linezolid combined with other antimicrobial agents against Staphylococci, Enterococci, Pneumococci, and selected gram-negative organisms.

Authors:  Michael T Sweeney; Gary E Zurenko
Journal:  Antimicrob Agents Chemother       Date:  2003-06       Impact factor: 5.191

2.  Synergistic effects of vancomycin and β-lactams against vancomycin highly resistant Staphylococcus aureus.

Authors:  Fumiaki Tabuchi; Yasuhiko Matsumoto; Masaki Ishii; Keita Tatsuno; Mitsuhiro Okazaki; Tomoaki Sato; Kyoji Moriya; Kazuhisa Sekimizu
Journal:  J Antibiot (Tokyo)       Date:  2017-02-15       Impact factor: 2.649

3.  In vivo synergism of ceftobiprole and vancomycin against experimental endocarditis due to vancomycin-intermediate Staphylococcus aureus.

Authors:  J M Entenza; T R Veloso; J Vouillamoz; M Giddey; P Majcherczyk; P Moreillon
Journal:  Antimicrob Agents Chemother       Date:  2011-07-05       Impact factor: 5.191

4.  Lack of bactericidal antagonism or synergism in vitro between oxacillin and vancomycin against methicillin-susceptible strains of Staphylococcus aureus.

Authors:  Christian Joukhadar; Satish Pillai; Christine Wennersten; Robert C Moellering; George M Eliopoulos
Journal:  Antimicrob Agents Chemother       Date:  2009-11-23       Impact factor: 5.191

5.  Synergy of β-Lactams with Vancomycin against Methicillin-Resistant Staphylococcus aureus: Correlation of Disk Diffusion and Checkerboard Methods.

Authors:  Cheng Len Sy; Tsi-Shu Huang; Chii Shiang Chen; Yao-Shen Chen; Hung-Chin Tsai; Shue-Renn Wann; Kuan-Sheng Wu; Jui-Kuang Chen; Susan Shin-Jung Lee; Yung-Ching Liu
Journal:  J Clin Microbiol       Date:  2015-12-16       Impact factor: 5.948

6.  Interactions between glycopeptides and beta-lactams against isogenic pairs of teicoplanin-susceptible and -resistant strains of Staphylococcus haemolyticus.

Authors:  Carla Vignaroli; Francesca Biavasco; Pietro E Varaldo
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Vancomycin and oxacillin co-resistance of commensal staphylococci.

Authors:  Ariyo Oludotun Soyege; Adedayo Olajide Ajayi; Elvis Ngwenya; Albert Kotze Basson; Anthony Ifeanyin Okoh
Journal:  Jundishapur J Microbiol       Date:  2014-04-01       Impact factor: 0.747

Review 8.  Ceftobripole: Experience in staphylococcal bacteremia.

Authors:  A Soriano; L Morata
Journal:  Rev Esp Quimioter       Date:  2019-09       Impact factor: 1.553

9.  Synergy between vancomycin and nafcillin against Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Steven N Leonard
Journal:  PLoS One       Date:  2012-07-24       Impact factor: 3.240

10.  CAMERA2 - combination antibiotic therapy for methicillin-resistant Staphylococcus aureus infection: study protocol for a randomised controlled trial.

Authors:  Steven Y C Tong; Jane Nelson; David L Paterson; Vance G Fowler; Benjamin P Howden; Allen C Cheng; Mark Chatfield; Jeffrey Lipman; Sebastian Van Hal; Matthew O'Sullivan; James O Robinson; Dafna Yahav; David Lye; Joshua S Davis
Journal:  Trials       Date:  2016-03-31       Impact factor: 2.279
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.